RxDoctor Payments DataLook up a doctor →

Alejandro Pla, MD

Nephrology · Pembroke Pines, FLNPI 1780649376

Payments from drug & device makers

$371,164in general payments, 2019–2025

Across 466 payments — averaging $796.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$243K
  • CSL Behring$123K
  • Amgen$2K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$590
  • Bayer$439
  • plus $2K from 9 others

What the payments were for

  • Speaking & faculty fees$1,44025%
  • Food & beverage$4,12470%
  • Education$3105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$371,164 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$440,508
Medicare patients
411
Services billed
8,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide81$159,363
VeltassaPatiromer Calcium Sorbitex124$129,127
FarxigaDapagliflozin Propanediol85$75,744
LokelmaSodium Zirconium Cyclosilicate86$70,412
JanuviaSitagliptin Phosphate30$22,338
Cinacalcet Hcl23$9,046
LinzessLinaclotide14$7,341
Sevelamer Carbonate67$4,932
Calcium Acetate51$2,879
Midodrine Hcl18$1,507
Bumetanide79$1,053
Nifedipine ErNifedipine48$871
Furosemide200$680
Labetalol Hcl17$533
Allopurinol131$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$109$159,36381 claims
AstraZenecaFarxiga, Lokelma$1,103$146,156171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →